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Introduction 
 Diabetes Mellitus is a metabolic cum vascular disease, cause of which 
is mainly due to defect in insulin secretion from the β cell of islet of 
pancreas or defect in the action of insulin1,2. Diabetes mellitus is marked by 
chronic high glucose concentration in plasma.  The resultant hyperglycemia 
which in long run lead to serious damage and dysfunction of many vital 
body organs especially the blood vessels and nerves.  Symptoms of diabetes 
recognition dates back to 1550 B.C where diabetes was described as 
melting3 down of the flesh and limbs into urine and for the patients never 
stop making water.  Diabetes in Greek means siphon – to explain the 
liquefaction of the flesh and boned into urine; Mellitus means honeyed 
urine). 
Epidemiology  
Diabetes Mellitus is a major threat to the public health in this world. The 
entire globe is now facing a new hazardous challenge in the form of growing 
epidemic of diabetes mellitus. Diabetes mellitus is well known for its 
potentially devastating damage and dysfunction to the organs from head to 
toe and can occur in all age group from pediatric population to geriatric 
population. Diabetes which was once thought as a disease of rich people is 
 now stirring up often in poor rural population. Thus Diabetes has become a 
common disorder and that too life threatening disease with dramatic increase 
all over the world.  Facts about diabetes that was released by World Health 
Organization are alarming and urge to take prompt preventive measures. 
 
 
1. Worldwide there are 171 million people living diabetes and this 
number of people living with diabetes may double
2. During the next 25 years there may be augmentation in diabetic 
population by 150% especially in developing countries
2 
 by 2030
 
 
1,3
. 
1,2
.  
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3. There is a gross change in the age of people living with diabetes 
between developed and developing countries. Diabetic populations in 
the developed countries are above the age of retirement whereas in 
developing countries they clump in the working age population 
especially between the age group between 35 and 60 years.  
4. The reason for this escalation in diabetes is due to population ageing, 
increasing trends towards obesity, sedentary life style. Unhealthy food 
habits also contribute to the high incidence of diabetes.  
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5. Diabetes contribution to mortality rate is very high. Every year 
diabetes attribute to 3.2 million deaths1,3 which can be simplified as 
diabetes contribute to one in 20 deaths or in other words six deaths per 
minute. In days 8,700 deaths occurs due to diabetes per day. 
6. As mentioned earlier that diabetes is common in middle aged persons 
in developing countries, diabetes causes high mortality by being the 
etiology or part of etiology in one in ten deaths between the age group 
of 35 to 64 years old.  
7. For a diagnosed case of diabetes there is hiding case which has to be 
explored. In the fact sheet released by IDF there are about 50% 
diabetes population are living who are not yet diagnosed.                      
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Prevalence of Diabetes in INDIA: 
      ICMR-INDIAB is the largest recent study conducted exclusive to 
analyze the impact of Diabetes in different regions of India. Results from the 
phase I of ICMR-INDIAB study was frightening and the epidemiological 
data about diabetes also differs in the various regions of India. In India, 62.4 
million people are living with diabetes which is very high on compare with 
the rest of the world. 77.2 million People in India are in pre diabetic stage 
which should be addressed and needs preventive measures at this juncture. 
 On dissecting the prevalence of diabetes among the regions of India, 
Chandigarh scores the high prevalence with 13.6 percent, followed by Tamil 
Nadu with 10.4 percent. Next in the order is Maharashtra with 8.4 percent 
followed by Jharkhand with 5.3 percent.  This data shows that diabetes is 
prevalent throughout India without confining to North or Southern part of 
India and also blooming exponentially.  
 On converting the percentage into numbers of people living with diabetes in 
our state, around 4.8 million diabetic populations are living in Tamil Nadu. 
3.9 million People are in pre-diabetes stage which has to be taking in hand to 
reduce the further heave in the impact of diabetes in the state. Though the 
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number of people with diabetes is rising, the age of onset is decreasing with 
shift towards young middle age peoples of age group 25-34 years.   
 
 
 
In most countries where diabetes is highly prevalent, pre mature illness as 
well as premature death rate was high. Thus diabetes has emerged as one of 
the cause for premature death. Diabetes mellitus accelerate the rate of 
atherosclerosis as well as arteriosclerosis there by contributing to the 
increased risk of cardiovascular disease.  Cardiovascular disease is 
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responsible for between 50% and 80% of deaths in people with diabetes.  
Diabetes induced injury doesn’t confined to cardiovascular system. Diabetes 
is the one of the leading cause of visual loss, amputation and chronic kidney 
disease.  Diabetes complications not only affect the individual health. It in 
turn causes financial burden to the entire family and loss of man power to 
the society. One positive point at this juncture is that diabetes onset is 
preventable; diabetes complications are preventable in early stages. It is easy 
to prevent than to suffer the pain. Promising for healthy life prevents the 
onset of diabetes, periodic monitoring for emergence of complication 
prevents the diabetes complications. 
Diabetes: Changing Trend 
  Diabetes is arising as an epidemic especially in young age people which is 
a worrisome fact. The rise in diabetes mellitus among the young people is 
bewildering as the rise may be due to earlier age of onset of type 2 
diabetes19,20 or slow onset of type 1 diabetes.  
Recent studies show that due to restricted physical activity and consumption 
of high calorie diet in children, there is high incidence of childhood obesity. 
Obesity which sets the clock on for insulin resistance in childhood may 
contribute to the earlier development of type 2 DM at young age. The rise in 
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the earlier onset type 2 diabetes may be also due to urbanization and parental 
diabetes. Due to rapid increase in obesity among general population, even 
people diagnosed as type 1 diabetes are obese or overweight at the time of 
diagnosis22. 
 Diabetes related complication also occurs early than expected if diabetes 
occurs early. Thus apart from early onset of diabetes mellitus, these young 
individual are also prone to get vascular complication at an earlier stage 
which will be a great agony for the entire family. Thus differentiating the 
type of diabetes on the basis of weight or age of onset becomes baffling and 
needs further work up to classify the diabetes in young22,23. 
 On analyzing the pathogenesis of these two major types of diabetes, 
autoimmune damage of β- cells of pancreas by various auto antibodies is the 
major cause for type 1 diabetes.  To classify as well as to differentiate type 1 
DM from type 2 DM in addition to clinical presentation, identification of 
auto antibodies18 to the β- cells of islet of pancreas becomes much essential 
in youth population. Knowledge about the presence of these autoantibodies 
to Insulin as well as islets of pancreas especially in overweight and obese 
young people with diabetes can guide about decisions regarding initiation of 
insulin therapy at an early stage to achieve euglycemia and avoid diabetes 
related complication.  
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Need of the study: 
There are several studies such as UKPDS which have demonstrated the 
presence of auto antibodies like GAD 65 in peoples diagnosed as type 2 
diabetes phenotypically. To  assess the presence of auto antibodies in young 
peoples diagnosed as type 2 diabetes phenotypically in our community, I 
have planned to conduct this study at the Institute of Internal Medicine and 
Institute of Diabetology, Madras Medical College, Rajiv Gandhi 
Government General Hospital, Chennai for a period of 6 months from--------
--------------------- 
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Aims and Objective 
1. To study the presence of GAD and IA-2 antibodies in young adults 
diagnosed as Type 2 Diabetes phenotypically. 
2. To assess the ability of auto antibodies to discriminate between 
Type 1 diabetes and Type 2 diabetes whose treatment differs. 
.   
 
 
 
 
 
 
 
 
 
 
11 
 
Review of Literature 
 
Diabetes Mellitus is a metabolic cum vascular disease characterized by 
chronic hyperglycaemia that is due defects in insulin secretion or insulin 
action or both. Diabetes mellitus is associated with long-term damage of 
organs especially blood vessels, eyes, kidneys and heart. Thus diabetes leads 
to deterioration of function of different organs and makes debilitating quality 
of life of the individual.  
 
Symptoms of diabetes3,4: 
  Half of the patients with diabetes are asymptomatic and detected on 
investigations done for other purpose or during health screening. 
 Classical symptoms are frequent urination, excessive thirst, weight 
loss. But diabetes may be detected first time with presentation of diabetic 
keto acidosis or even with long term complication like retinopathy or 
nephropathy. Diabetes may be cause or association with various diseases 
like fungal infection especially over external genitalia, non-healing ulcers, 
visual disturbances etc. 
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Complication of diabetes: 
Diabetes complication can be divided as life threatening acute complication 
which necessitate immediate intervention to save the life of the individual 
where as long term complication are majority due to advanced glycation end 
products (AGE) that needs to be prevented than to be treated. Acute 
complications are metabolic in nature whereas chronic complications are 
vascular.  
 
 
Symptoms
of
Diabetes
Asymptomatic
for 
Diabetes
Classical symptoms:
•Polyuria
•Polydipsia
•Weight loss
DM associated with
Blurring of vision
Fungal infection 
Non healing ulcers
Skin disease
13 
 
 
Long-term complications of diabetes are grouped as microvascular and 
macro vascular complication. Microvascular complications include 
retinopathy, nephropathy and peripheral neuropathy. Patients with diabetes 
have an increased incidence of atherosclerotic cardiovascular, peripheral 
arterial and cerebrovascular disease. Hypertension and abnormalities of 
lipoprotein metabolism are often found in people with diabetes and which if 
present can aggravate the complication of diabetes more aggressively. 
 
Diagnostic criteria for Diabetes1,4,5 
 On contrast to other endocrine disease where hormone levels were 
determined for the diagnosis, diabetes is diagnosed by estimating the glucose 
level in the sera of the patients. Oral glucose tolerance test (OGTT) is the 
diagnostic test recommended by WHO till date for the diagnosis of diabetes.   
 OGTT would be administered in the morning after the patients has had at 
least 3 days of unrestricted diet and usual physical activity. The test should 
be done overnight fast of at least 8 hr. during which patient may drink water. 
After collecting the fasting blood sample, the subject is allowed to drink 
75gram of anhydrous glucose in 200-300 ml of water over a period of 5 
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minutes. Blood was drawn at 2 hours of ingestion of glucose. The blood 
samples are to be immediately centrifuged promptly to separate out the 
plasma and to be analyzed immediately.  
 
Category Venous plasma glucose 
in mgs/dl (mmol/L) 
Diabetes Mellitus 
Fasting plasma glucose 
2hr post glucose load 
 
   ≥ 126mgs/dl (≥ 7.0 mmol/L)     
   ≥ 200mgs/dl (≥ 11.1 mmol/L)    
Impaired glucose tolerance (IGT) 
Fasting plasma glucose  
 
2 hr post glucose load 
 
< 126 mgs/dl (< 7.0 mmol/L) 
 
     140 mgs/dl to 199 mgs/dl  
   (7.8 mmol/L to 11.1 mmol/L)    
Impaired fasting glucose(IFG)  
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Fasting plasma glucose 
 
 
2 hr post glucose load 
      110 mgs/dl  - 125 mgs/dl 
     (6.1 mmol/L  to 6.9 mmol/L)  
 
< 140mgs/dl ( <7.8 mmol/L)    
 
The above diagnostic criteria were adapted from consensus statement of 
World Health organization (WHO), Geneva and International Diabetes 
Federation (IDF).  
OGTT will not only diagnose diabetes, but also identify two other categories 
such as Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose 
(IFG) which are forerunner for diabetes mellitus. 
 
Classification of Diabetes Mellitus1,2 
Earlier classification of Diabetes Mellitus was based on the age such as 
juvenile onset diabetes mellitus for type 1 diabetes mellitus and adult onset 
diabetes mellitus for type 2 diabetes mellitus. Subsequently diabetes is 
classified on basis of the treatment aspect especially on the need of insulin 
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such as Insulin dependent diabetes (IDDM) for type 1 diabetes mellitus and 
non-insulin dependent diabetes (NIIDM) for type 2 diabetes mellitus. This 
classification was confusing as patients with any form of diabetes may 
require insulin treatment at some stage of their disease. 
 
 Hence recent classification of Diabetes Mellitus by WHO and American 
Diabetic Association was based on the etiopathogenesis which address the 
pathophysiology involved in the process of the complex disease like 
diabetes. This classification leads to better understanding about the disease, 
ease the mode of treatment and paid the way for preventive aspects about the 
diabetes. 
CLASSIFICATION OF DIABETES: 
 Type 1 Diabetes Mellitus 
  a-autoimmune 
  b-idiopathic 
 Type 2 Diabetes Mellitus 
 Gestational Diabetes Mellitus 
17 
 
 Secondary Diabetes Mellitus 
Gestation Diabetes Mellitus – 
      Defined as any degree of glucose intolerance that is associated with 
hyperglycemia of variable severity with first time detection during 
pregnancy 
Maturity Onset Diabetes of the Young (MODY).  
MODY is a type of diabetes associated with β-cell dysfunction resulting 
from a specific mutation in MODY related gene. It is due to Genetic defects 
of β-cell function in the form of impaired insulin secretion which is the 
prime defect. There may be minimal or no even defects in insulin action. 
Inheritance pattern of MODY is autosomal dominant. As it is difficult to 
perform genetic studies in all clinical criteria can be utilized for the 
diagnosis of MODY.  
 Obesity is not need to present in patients with MODY mutations and 
obesity is unlikely to be a consistent feature. MODY is characterized by 
onset of hyperglycemia at an early age, generally before age 25 years. 
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Drug or chemical-induced: 
   Diabetes occurring secondary to drugs or toxins are not 
common as that of type 2 DM. These drugs on long term can cause diabetes 
either by producing resistance to the insulin pharmacological action and can 
have direct injuries effect on β-cell of the pancreas there by producing 
secretary defect. Few of such drugs are          glucocorticoids, thiazide 
diuretic, nicotinic acid, immunosuppressant like cyclosporine4 and its 
followers, pentamidine, diazoxide 3,4etc. 
Diabetes and genetic syndromes: 
Diabetes occurs as part of some genetic syndromes like Down syndrome, 
Turner syndrome, Wolfram syndrome, Klinefelter syndrome 
       Diabetes in Friedreich’s ataxia is common endocrine abnormality which 
is present in 20% due to both insulin resistance and secretory defect. In 
Ataxia telangiectasia, there is high incidence of type 1 DM.  
 
Pre diabetes:   
 Pre diabetes is stage prior to the onset of frank diabetes. People with 
prediabetes will have blood sugar more than the normal limits but not high 
19 
 
enough to be called as diabetic. It comprises impaired glucose tolerance and 
impaired fasting glucose. If not intervened with life style changes about 11% 
will develop full blown type 2 diabetes as per ADA statement. Hence pre 
diabetes should be used as an opportunity to avoid diabetes as it is a 
reversible state. 
Impaired Glucose Tolerance (IGT) 
Impaired Glucose Tolerance (IGT) is a stage in which individuals glucose 
tolerance is above the conventional normal range but lower than the level 
considered diagnostic of diabetes. Clinical importance of IGT is high risk for 
developing frank diabetes and macrovascular complication. IGT is 
associated with insulin resistance and most of these persons are obese or 
over weight. IGT can be taken as platform to educate and halt the 
progression to frank diabetes by life style interventions. 
Impaired Fasting glucose (IFG) 
Impaired Fasting glucose (IFG) is also a stage of impaired glucose 
homeostasis. Whose fasting glucose levels were above normal but below 
those diagnostic for diabetes. This group is also highly vulnerable to get 
diabetes and can be prevented by life style changes.  
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Consequences of diabetes 
Diabetes is well known disease that produce complication on long term to 
various organs in the human body in particular to the blood vessels to the 
heart, brain, kidney, eyes and have a strong predilection towards damaging 
the nerves. 
• Diabetes increases the risk of heart disease as well as 
cerebrovascular accidents. As well known that major cause of 
death in diabetic people is due to cardio vascular disease 
accounting to 50% of people1,3. Diabetes is one of the major causes 
of silent myocardial infarction by causing dysfunction in 
autonomic nervous system. The risk of coronary artery disease in 
diabetes population is about 2 to 4 times than the general 
population. Diabetes people develop coronary artery disease in 
advance about a decade earlier.  
• Diabetes increases the risk of chance of getting a foot ulcer, the 
gate way to limb amputation. Foot ulcers in diabetic patients are 
due to combined damage to the nerves of the limbs and occlusion 
of the arterial tree supplying the limbs. Diabetes is the leading 
cause for non-traumatic foot amputation and diabetic feet are at 
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high risk with about 15 – 401,3,4 times more likely to have a lower 
limb amputation compared to the general population 
• Worldwide estimation about the blow of diabetes on eye is that 
more than 2.5 million people’s eyes are affected by Diabetes. In 
industrialized nations, Diabetic retinopathy is the leading cause of 
vision loss. Pathetic situation in this disease is that the loss of 
vision due to diabetes is more prevalent in the working age group 
individuals i.e., in the age of 20 to 65 years.  
• Diabetes damages the kidney which occurs after few years of onset 
of diabetes. Diabetes is one of the leading causes for chronic 
kidney disease which can be easily prevented by estimation of 
urine for albumin and reverted by use of pharmacological agents 
like ACE inhibitors or ARB. It is estimated that mid-way between 
10-20% people with diabetes die of kidney disease.  
• Damage to nerves by diabetes is the most common long term 
complication affecting more than 50% of persons with diabetes. 
Diabetes damages all the nerves like sensory, motor, autonomic in 
isolation or in combination. Diabetes also affects the cranial nerves 
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like facial nerve and oculomotor nerve. Diabetes affects the 
oculomotor nerve with sparing the papillary fibers.   
Though diabetic neuropathy can present with different expressions, common 
clinical presentation are tingling, pain, numbness, or weakness in the feet 
and hands. On long term, damages to these nerves presents with reduced 
sensation making these feet for high risk for formation of foot ulcers and 
eventual amputation. 
• Diabetes makes the person to die a decade before than people 
living without diabetes3.  
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Impact of Diabetes in India:   
 
  Prevalence of diabetes is increasing in India tremendously on 
par with the rest of the world. As per the diabetes atlas of International 
Diabetes Federation released in the year 2007, about 40.9 million diabetes 
people are living in India and this number may increase to 69.9 million3.  
Diabetes patients in Asian Indian differ from that of western population with 
diabetes in many aspects such as younger age onset, less obesity and genetic 
factor play a major role.  
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From the Chennai Urban Rural Epidemiology Study (CURES)10following 
facts about the impact of Diabetes in India were obtained 
• Prevalence of Diabetic retinopathy is 17.6% in south Indian 
population. Diabetic retinopathy can be broadly divided into Non-
proliferative diabetic retinopathy and proliferative diabetic 
retinopathy. NPDR is again sub classified into early, mild, moderate 
and severe depending upon the presence of microanuerysm, soft and 
hard exudates, IRMA- intra retinal microvascular abnormalities, dot 
and flame shaped hemorrhages. Proliferative diabetic retinopathy is 
characterized by the presence of neovascularization over the optic 
fundus.  
• Prevalence of overt diabetic nephropathy is 2.2%13 and  
Microalbuminuria was present in 26.9%. Microalbuminuria is the earliest 
clinically detectable stage of diabetic kidney disease which at appropriate 
intervention can retard or reverse the progress of the disease. 
Microalbuminuria also severs as a marker for endothelial dysfunction 
there by a risk factor for cardio vascular disease. 
• 3.2% of the diabetes population in India has peripheral vascular12 
disease in India.  
25 
 
• Coronary artery disease prevalence in Indian diabetic is 11% as per 
the Chennai Urban Population Study (CUPS)9.  
Aetio-pathogenesis: 
Regarding etio-pathogenesis, majority of cases of diabetes fall into two 
broad categories known as type 1 and type 2 diabetes. Diabetes is a complex 
disease where combinations of multiple genes and environmental factors 
play a pivotal role leading to loss of β –cell of pancreas thereby causing 
hyperglycemia. Underlying pathogenesis resulting β-cell loss of pancreas is 
quite diverse in the subtypes of the disease that ends in progressive cell 
failure and hyperglycemia as sequel.   
Type 1 Diabetes Mellitus16: 
 Type 1 DM most commonly results from a chronic autoimmune 
destruction of the pancreatic islet β cells. This process would have probably 
initiated by exposure of a genetically susceptible host to an environmental 
agent. These patients are prone to ketoacidosis on comparison to type 2 DM.  
The pathogenesis in type 1 diabetes mellitus is mostly caused by an 
autoimmune assault against the β-cells of pancreas inducing progressive cell 
death. Whereas the pathogenesis in case of type 2 diabetes is more variable. 
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It involves different degrees of β-cell failure due to interaction between 
insulin resistances and insulin secretory defect.  
Thus diabetes mellitus is etiologically and clinically heterogeneous group of 
disorders that share hyperglycemia in common. For hyperglycemia to be 
identified in type 1 diabetes, at least 80-90% of the functional capacities of 
the β cells should be lost. Exogenous administration of Insulin is the only 
treatment modality for these patients and its must for their survival 
Natural history of type 1 DM: 
 Natural history of Type 1 DM includes the following major components.  
Preclinical autoimmunity:  
In this stage, there is an immunological assault on the β cells of the pancreas 
which leads to progressive loss of the β-cell function. This duration of this 
stage is variable and may extend from months to years prior to the diagnosis 
of diabetes by upto 9-13 years. Autoantibodies and T –cells reactive with β-
cell antigen can be detected at this stage. Insulin secretion ranges from 
normal to low with normal glucose in the serum. 
Hyperglycemic stage or clinical onset stage: 
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 At this stage 80-90% of the functional capacities of the β-cells are lost. 
Patients present clinically with polyuria, polydipsia, and weight loss. 20-
40% present as diabetic ketoacidosis. Immune markers of type 1 DM such as 
GAD-65, IA-2 are evident in this stage. Insulin secretion is low. 
Remission stage:  
This is a transient phase only in the natural history of type 1 DM. There is a 
transient fall in the requirement of insulin due to an improved β-cell 
function. Total as well as partial remissions have been reported. Older the 
age of onset and less severe the initial presentation, absent autoantibodies 
are consistent with longer remission. In this stage Insulin independence can 
be seen in 20-70%, blood sugar may be normal or mildly elevated. It is 
unclear about the mechanism behind the remission. Remission is possible if 
the offending factor is removed as in the case of type 1 DM occurring due to 
viral infections or exposure to dietary factors that would have triggered 
autoimmunity. 
Established diabetes: 
 This stage is long standing diabetes where both acute complications like 
ketoacidosis and chronic complications like retinopathy, nephropathy, and 
neuropathy are common. Prevalence of autoantibodies decreases in this 
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stage and endogenous insulin; c-peptide secretions are progressively lost. 
These patients require insulin for their survival and periodic monitoring for 
complications is must. 
 Most of the type 1 diabetes patients are non-obese. The presence of 
obesity is not incompatible with the diagnosis. Immune-mediated diabetes 
commonly occurs in childhood and adolescence, but it can occur at any age. 
The rate of β-cell destruction is variable especially rapid in children and 
slower in adults. Genetic, Environmental, dietary factors may have doubtful 
role in the pathogenesis of type 1 DM.  
Genetic factors: 
The prevalence of β-cell autoimmunity in first degree relatives of type 1 DM 
is increased 3-5 times compared with no family history of type 1DM. High 
risk indicates in individuals heterozygous for HLA DR3/4, DQ2/8. 
Environmental factors:24 
Viruses and components of early childhood diet may cause type 1 DM.  
In viruses21 – rubella, mumps, herpes viruses have been implicated. Increase 
in the incidence of type 1 DM in patients with congenital rubella syndrome 
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is obvious and set forth virus infection can be enrolled in the causative agent 
for type 1 DM.  
Regarding dietary factors, breast feeding may be viewed as surrogate for the 
delay in the introduction of diabetogenic substances present in early 
childhood diet. Newly diagnosed type 1 DM children have higher levels of 
serum antibodies against cow’s milk – β lactoglobulin. Toxic doses of 
nitrosamine containing compounds and onset of type 1 DM is recognized. 
Type 2 Diabetes Mellitus: 
Type 2 diabetes is the most common form of diabetes where vast majority of 
diagnosed and undiagnosed diabetes fall in this category. Thus type 2 DM 
represent diabetes in the absence of type 1 DM or other specific type of 
diabetes. It is characterized by disorders of insulin action and secretion. 
Etiology of this form of diabetes in not known but auto immune destruction 
of the β-cells does not occur. Type 2 diabetes patients are overweight or 
obese.  The circulating insulin levels may be normal or elevated yet 
insufficient to control blood glucose levels because of insulin resistance.  
Type 2 diabetes occurs more frequently in women with prior gestational 
diabetes mellitus and in individuals with hypertension or dyslipidemia. 
Although type 2 diabetes is disease of old aged, now days they are 
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commonly diagnosed in young, mainly due to obesity epidemic. In Indian 
population where there is a high prevalence of Type-2 DM, many cases of 
diabetes occur in young to middle age and adults.  
Risk factors for Type-2 DM 
o  Positive family history –  
The empiric risk of family history contributing to Type-2 DM can be due to 
inherited susceptibility as well as sharing of similar same environment. 
o Genetic factors:  
 In contrast to Type-1 DM, genetic factors play a minor 
role in   contributing to susceptibility of Type -2 DM. 
Type – 2 DM is a complex multi genetic disorder with 
presence of loci on chromosome 1.  
o Obesity:  
 Obesity is a powerful predictor of Type-2 DM. Visceral 
obesity which can measured by waist circumference or 
waist hip ratio is the important determinant of risk than 
body mass index. 
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o Gestational diabetes mellitus:  
 Women with history of GDM are at risk of developing 
Type-2 DM later. 
o Other risk factors: 
  Physical inactivity,  
 Dietary factors like consumption of high glycemic index 
with trans-fatty acid diet.  
 Polycystic ovarian syndrome, 
 Metabolic syndrome,  
 Pre diabetes like IGT and IFG.  
 
Pathophysiology in type 2 DM:  
  Pathophysiology involves both insulin resistance at the peripheral tissue 
where insulin acts and decline in insulin secretion due loss of function β-
cells in the islets of pancreas.  
 
32 
 
Insulin resistance: 
 Insulin resistance is a state in which a given concentration of insulin 
produces a less than normal biologic response. The etiology of insulin 
resistance at the tissue level especially liver, adipose tissues are not clear. 
Causes of insulin resistance can be categorized on the basis of etiologic 
mechanisms like 
1. Abnormal β-cell secretory defect 
2. Circulating insulin antagonists- 
• excess counter regulatory hormones , 
• Elevated free fatty acid level 
3. Target tissue defect in insulin action- insulin receptor defect 
Insulin resistant states share some common somatic features like acanthosis 
nigricans, hirsutism which may be due to high level of circulating insulin 
that is capable of binding into IGF-1 receptors stimulating growth and 
proliferation of various cell types. 
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Impaired Insulin secretion: 
Islet dysfunction in Type -2 DM is not certain whether the defect in insulin 
secretion is due to loss of β-cell mass or defect in the function of β cells. The 
reduction of islet cell mass is mainly due to loss of β-cells with normal other 
cells of islet like α cells. The loss of β-cell mass is due to deposition of 
amyloid peptide that is co secreted along with insulin. This amyloid peptide 
deposition leads to islet fibrosis. For the development of fasting 
hyperglycemia and secretory defect, greater loss of β-cell mass of at least 
50% reduction with insulin resistance must. 
In initial stages of Type 2 diabetes mellitus, euglycemia can be achieved 
with help of medical nutrition therapy and oral anti diabetic drugs. Insulin is 
required for control of blood glucose as the disease progress in addition to 
pharmacological treatment.  
 
Indication for insulin in Type 2 DM: 
• Uncontrolled diabetes with strict adherence to medical nutrition 
therapy and maximum dose of oral hypoglycemic drugs. 
• Profound weight loss due to uncontrolled hyperglycemia 
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• Type 2 DM patients planning to pregnancy whose blood sugar 
is uncontrolled with oral agents. 
• Severe hypertriglyceridemia 
• Surgery in type 2 DM 
• Florid sepsis with hyperglycemia where blood sugar has to be 
controlled instantly to save the life 
• Acute Diabetes complication like diabetic ketoacidosis, hyper-
osmolar non ketotic coma. 
Prevention 
Prevention should be the prime initiative at this moment to halt the alarming 
rise of diabetes in our population.  Preventative care need not involve costly 
treatment or medication.  Preventive measures can be categorized as primary 
prevention i.e. measures to reduce the new onset diabetes mellitus in the 
community and secondary prevention i.e., the measures to be taken to reduce 
the occurrence of diabetes complication.  
From the analysis of CURE study it has clearly mentioned that only 22.2% 
of the whole population and 41.0% of the known diabetic subjects were 
aware that diabetes could be prevented. It also states that awareness and 
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knowledge regarding diabetes is still grossly inadequate in India. Massive 
diabetes education programmes are urgently needed both in urban and rural 
India.  
Primary prevention of new onset diabetes 
Type 1 DM 
Primary prevention in case of type 1 DM can be targeted for the people with 
high risk like positive history of type 1DM in any of the family members. 
Incidence of Type 1 DM is very high in the first degree relatives of 
established type 1 DM patients. These high risk patients are to be screened 
for detection of auto antibodies than screening the entire population. 
Preventive measure adopted was giving prophylactic low dose insulin for 
these patients. But the results of these trials showed no efficacy in 
preventing or even delaying the onset of diabetes. Several approaches were 
carried out to prevent the onset of type 1 diabetes. No approach was 
beneficial and none of them have been shown to work.  Preventive aspects 
of type 1 diabetes remain an objective for the future till date. 
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Type 2 DM 
Preventive aspects hold very well in type 2 diabetes. Measures such as 
adopting simple lifestyle have shown to be effective. These activities are 
useful not only in preventing but also delaying the onset of type 2 diabetes.  
1. Healthy balanced diet – avoiding high calorie foods rich 
in trans fatty acid is helpful. 
2. Avoiding sedentary leisure activities with a goal to 
improve physical activity 
3. Weight loss in order to maintain ideal body weight 
4. Quit smoking habit. 
Secondary Prevention of diabetes; 
Type 1 DM: 
Secondary prevention in new onset type 1 DM was not fruitful to increase 
the rate and duration of type 1 DM remission. Immunosuppressive therapy 
with drugs like cyclosporine were tried but was not successful. 
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Regarding prevention of diabetic complication, DCCT – diabetes Control 
and Complication Trail has demonstrated that intensive insulin therapy can 
delay the onset and even slow the progression of diabetic complication 
Type 2 DM: 
Complications of diabetes can be prevented or delayed through effective 
management.  Treatment of diabetes is not only concerned with lowering 
glucose, but also involves monitoring as well as reduction in the risk factors 
for diabetic complications such as control of blood pressure and blood lipids.  
People with type 2 DM can be managed with life style changes, oral drugs to 
control blood sugar and sometimes insulin to control blood sugar.  People 
with type 1 diabetes require insulin for their survival. 
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Stages of Diabetes: 
 
 
Type 1 DM which has high incidence rate in younger age especially before 
the age of 20 with a peak around puberty.  Type 1 DM also occurs in middle 
aged people which are often not appreciated because of greater frequency of 
Type 2 DM in that age group.  Hence it becomes dilemma to classify these 
patients as type 1 DM or Type 2 DM whose treatment is going to differ to 
achieve glycemic control.  Detection of antibodies which are characteristic 
of type 1 DM in these patients can differentiate this type 1 DM from similar 
clinical phenotype of type 2 DM.  This subset has been described as Latent 
autoimmune diabetes in adults, late onset type 1 DM or type 1.5 diabetes.  
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Latent Autoimmune Diabetes of Adult: 
 LADA are those patients with type 2 diabetes phenotype with presence of 
auto antibodies to islet or insulin and slowly progressive β –cell failure. 
Studies like UKPDS reveal that between 5%-30% of patients initially 
thought as type 2 DM are found to be  
Type 1. Expression of autoantibodies to islets like GAD -65 in these patients 
becomes then paramount importance for diagnosis. In countries like Japan, 
majority of type 1 diabetes cases develop in adults.  
Regarding HLA alleles, these patients resemble as that of type 1 diabetes 
with less frequent of DQ8/DQ2. Autoimmune β – cell destruction process in 
LADA proceeds more slowly in these middle aged people on comparison 
with young patients with classical type 1 DM.  Obesity does not exclude the 
diagnosis of LADA. It’s also knows slow onset type 1 DM or autoimmune 
diabetes of adult onset (ADA) 
Clinically these patients present as weight loss, unstable blood glucose levels 
and extremely diminished C-peptide. Prospective observation of these 
patients disclosed the clinical finding which included a late onset, positive 
family history of type 2 DM, slow progression of β – cell failure over 
several years with incomplete β – cell loss. 
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 Regarding treatment of these patients, oral hypoglycemic therapy will be 
ineffective and these patients are prone for ketoacidosis, Insulin becomes the 
choice of therapy. Immediate initiation of insulin in these patients is 
associated with preservation of C-peptide secretion. On contrary to type 1 
Diabetes these patients can be treated with low doses of insulin.  
From the above discussion it is very apparent that without determination of 
islet antibodies, it is not possible to separate type 1 diabetes from type 2 
diabetes among obese young adults. 
Autoantibodies 
  Regarding the recognization of target auto antigen there has been 
remarkable progress for the past 2 decades. Earlier islet autoantibodies was 
the cytoplasmic islet cell antibody (ICA) which was less specific in 
diagnosing type 1 DM. Autoantibodies reactive with antigens contained in 
pancreatic islet cells are common in type 1DM.   
Auto immune process in Type 1 DM is most commonly characterized on the 
presence of auto antibodies such as ICA, IAA, GAD and   IA-2. There is a 
remarkable inverse relationship between the age at which diabetes develops 
and the levels of insulin auto antibodies.  
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Epidemiological studies have clearly defined autoimmunity as the presence 
of auto antibodies in contrast to cellular markers as measurement of 
autoantibodies is reliable and standardized across laboratories. These auto 
antibodies are sensitive and predictive in diagnosing type 1 DM in general 
population. 
The best current predictor for the development of type 1A diabetes is the 
expression of two or more islet auto antibodies like GAD-65, IA-2, IAA, 
ICA. 80% of individuals developing type 1A diabetes express two or more 
of these auto antibodies 
ICA – (Islet cell antibody) 
Islet cell antibody assay was the earliest test done to predict or diagnose type 
1 DM.  These auto antibodies are called restricted or selective and these are 
associated with relatively low and slow progression t diabetes. The detection 
of ICA in the absence of the other autoantibodies is associated with a very 
low risk of progression to diabetes.  There is also difficulty in 
standardization of this test with poor reproducibility in laboratories. In final, 
detection of ICA in the absence of the other auto antibodies is associated 
with a very low risk of progression to diabetes. 
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Insulin auto antibodies (IAA) 
It was the first islet auto antigen to be present especially in children 
diagnosed as type 1 DM before the age of 5 years.  If diagnosed after the age 
of 15 years, insulin auto antibodies will be difficult to demonstrate in half of 
the people.  Insulin auto antibodies can develop in patients treated with 
insulin including human insulin after months of therapy.  Methods of 
detection of IAA are also cumbersome with ELISA or fluid phase radio 
assays which also require large volume of serum. There is a chance of trans 
placental transfer of insulin antibodies that usually disappear by 6 month of 
life but may persist up to 1 year. Thus, IAA provides no information relative 
to the diagnosis of Type 1 DM in middle aged person and persons treated 
with insulin. 
Glutamic acid decarboxylase (GAD) 
GAD is one of the most important assays used to diagnose type 1 DM. GAD 
exists in two major isoforms, GAD-65, GAD-67 where GAD-65  is the 
immunogen during β-cell destruction.  Expression of GAD is relatively 
common for patients with type 1 diabetes.  Although GAD distribution is 
found in neural tissue, antibodies to GAD-65 are predominantly associated 
with type 1 DM.  GAD auto antibodies are also seen in rare neurologic 
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disorder like stiffman syndrome. GAD antibodies may provide useful data in 
detecting auto immune destruction particularly in population screening. 
 Insulinoma associated protein 2 auto antibodies (IA-2) 
IA-2 auto antibodies were detected to about 70% in patients with new onset 
type 1DM. IA-2 have sequence homology to tyrosine phosphatase like 
molecules without any enzyme activity.  This autoantibody is probably the 
most specific of the antibodies identified to date. When IA-2 auto antibodies 
are detected, individuals usually express GAD 65 or IAA. For few 
individuals, IA-2 auto antibodies may be the only autoantibody detected in 
the pre-diabetic phase of the disease. 
Following are the study that clearly illustrates the importance of 
autoantibodies in the pathogenesis of type 1 diabetes mellitus. 
Heike E.Naserke et al (1998), In this study they analyzed the epitope 
maturation of IA-2 autoantibodies from the birth. The results of this study 
gave a picture that antibodies to IA-2 were found to be a risk factor for type 
1 diabetes mellitus. The study also highlighted the fact that these 
autoantibodies were high in prevalence in young individuals who are at risk 
of type 1 diabetes mellitus. 
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Anette-G.Ziegler et al (1999)- This study was conducted in the off-springs 
of type 1 diabetes mellitus patients for the appearance of autoantibodies and 
development of type 1 diabetes mellitus. Detection of autoantibodies such as 
GAD, IA-2 and IAA were performed in these patients at the time of birth 
followed by ninth month of life with subsequent analysis at second year and 
fifth year of age of these individuals. The results clearly showed that IAA 
was the prevalent autoantibody in children on comparison to other two 
autoantibodies. There was a strong co-relation with likelihood of 
development of type 1 diabetes. Earlier appearance of these autoantibodies 
showed the faster destruction of the beta cells of the pancreas resulting in 
earlier development of type 1 diabetes. 
Borg.H et al (2001) – This study showed the high prevelance of antibodies 
to GAD and IA-2 that foretells the β-cell failure in patients with new onset 
of type 1 diabetes in adult age. They also demonstrated that presence of 
these autoantibodies is associated with low fasting plasma C-peptide levels. 
On conclusion it is clear that high level of autoantibodies to GAD-65 as well 
as IA-2 can predict the destruction of β-cell of pancreas and eventual 
development of type 1 diabetes especially in the adult population. 
Katelijn Decochez et al (2000) – This is another study which clearly 
revealed the loss of β cell function in patients with autoantibodies like 
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GAD,IA-2 as well as ICA in the age group of people with diabetes less than 
40 years of age. 
Kimpimake.T et al (2000) – This study correlated presence of autoantibodies 
with genotyping in the individual of type 1 diabetes mellitus.  Genotyping 
was done both in type1 diabetes and in their siblings using the PCR 
technique. Autoantibodies were assessed by radiobinding assay for IAA, 
GAD and IA-2. At the conclusion it clearly said that type 1 diabetes patients 
showed increased HLA susceptible gene and increased titres of various 
autoantibodies. Thus autoantibodies can be used as surrogate markers for the 
diagnosis of type 1 diabetes mellitus due to auto immune destruction. 
Peter A.M.Weiss et al (2000) – This study investigated the impact of type 1 
diabetes during pregnancy. The results demonstrated that offsprings of these 
type 1 diabetes mothers had an increased risk for diabetes later in life with 
high relative risk for type 1 diabetes with 71.6% on comparison with relative 
risk of 3.2% for type 2 diabetes mellitus. 
Lindsay.R.S et al (2004) – This study was conducted on the cord blood from 
the off spring of mothers with type 1 diabetes mellitus for the analysis of 
autoantibodies such as IAA, IA-2 and GAD. They analyzed the influence of 
presence of these autoantibodies in utero with birth weight of the off-
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springs. These autoantibodies does not influence on the birth weight of the 
offspring born to type 1 diabetic mothers. 
Peter Achenbach et al (2004) – This is large cohort study conducted on 
relatives of patients who are positive for autoantibodies. In this study 
detailed examination was done that included determination of autoantibodies 
epitope specificity, titer and IgG subclass. Highest risk for type 1 diabetes 
mellitus was seen in the population showing high titer of IA-2 and IAA 
autoantibodies with IgG 2 and or IgG4 subclass of IA-2. 
Charlotta Nilsson et al (2007) – This study was unique as the study groups 
involved were women with gestation diabetes mellitus. This study was done 
to assess the frequency of β-cell specific autoantibodies in the women with 
gestational diabetes mellitus. Follow up of these women was done to 
estimate the risk of development of type 1 diabetes later. The results of these 
study showed that 6% of the study population were found to be positive for 
at least one of the autoantibodies to GAD-65, IA-2, IAA. On follow up of 
this high risk group, 50% of the women who are positive for autoantibodies 
developed type 1 diabetes on comparison with GDM women with antibody 
negative group. 
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Charles F.Verge et al (1998) – In this study they analyzed the precision of 
combined assay for autoantibodies like ICA,IAA,IA-2 and GAD-65 to 
forecast the severity of the disease in type 1 diabetes patients and their 
siblings and this study involved various population and conducted at 
different centers. The results from the various centers highlighted that IA-2 
was useful as a marker of type 1 diabetes mellitus and can be measured 
consistently without variations. Presence of multiple autoantibodies has 
achieved high sensitivity with low false positive rate. 
James M.Lagasse et al (2002) - This is a cohort study where presence of 
multiple autoantibodes were evaluated in school children with the median 
age of approximately 14 years of Washington state and study was followed 
up for a period of 8 years.  The study revealed that presence of single 
autoantibody was associated with slow progression of the disease 
whereaspresences of two or more autoantibodies are related with faster 
disease progression. 
Jeffrey P. Krischer et al (2003) - In this study all the four autoantibodies 
such as ICA, IAA, IA-2 and GAD were studied in the relatives of type 1 
diabetes mellitus. Study reported that presence of single autoantibody was 
more in subjects. Antibodies to GAD were found to be more sensitive than 
ICA. Increased sensitivity was found in the combination of IA-2 with GAD 
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with sensitivity of 97% in comparison to IA-2 plus ICA whose sensitivity is 
93%. 
In the DASP 2000 workshop, both GAD65 autoantibody and IA-2 
autoantibody radio immunoassays were found to have high sensitivity (80 
and 58%) and specificities (90 and 100%, respectively). The quest to 
identify one type of autoantibody as a better predictor than another has 
failed, because no clear order of appearance has been detected. Rather, 
several studies taken together suggest that the number of autoantibodies is 
predictive rather than the order of their appearance.  Individuals with two 
autoantibodies had a 68% 5 year risk for developing type 1 diabetes where 
as those with three autoantibodies had an estimated risk of 100% in 5 years.  
TrialNet oversight committee has proposed an antibody screening paradigm 
in which GAD65 Antibody and IA-2 Antibody in younger subjects, are all 
measured on initial screening 
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Need of the study: 
With the escalating epidemic of obesity in young adults, incidence of type 2 
DM is increasing especially before the age of 40 years.  On the other hand 
there is significant increase in the incidence of type 1 DM presenting as 
either overweight or obese.  Whether it is type 1 or type 2, glycemic control 
is the prime target to avoid diabetes related complication.  But the treatment 
part of type 1 diabetes differs from that of type 2 diabetes in achieving 
glycemic control.  
 Hence the clinical criteria to distinguish between type 1 or type 2 diabetes 
based on age at onset and obesity becomes difficult and this clinical 
misclassification leads to delay in achieving euglycemic level. Since in 
many population type 2 DM is either increasing in younger age or already 
the predominant form of diabetes in young is unanswered.  For a clinician to 
differentiate between type 1 and type 2 diabetes, the most direct way is 
assess the presence or absence of autoantibodies to islet of pancreas. 
Several studies in the past have clearly demonstrated the prevalence of auto 
antibodies against insulin or islets of pancreas in type 2 diabetes in overseas. 
Some studies correlated the antibodies level with prevalence of metabolic 
syndrome in diabetes.  The information regarding the phenotypic and 
50 
 
metabolic characteristics of these groups of patients is limited in comparison 
to the majority patients with type 2 diabetes without autoantibodies. 
In this study I am planning to assess the prevalence of auto antibodies – 
markers of beta cell dysfunction in newly diagnosed type 2 diabetes in 
young adults. This will help to identify the type of diabetes in young adults 
and will guide to initiate appropriate treatment to control hyperglycemia 
there by preventing chronic complications. 
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Materials and Methods 
This is a cross sectional study and it was conducted at Institute of Internal 
Medicine and Institute of Diabetology, Madras Medical College and Rajiv 
Gandhi Government General Hospital for a period of 6 months from----------
--------------. The protocol for this study was approved by Institutional 
Ethical Committee (IEC), MadrasMedicalCollege - 
RajivGandhiGovernment GeneralHospital, Chennai - 600003.  
Inclusion criteria for participation in the study 
1. Type 2 diabetes mellitus –phenotypically diagnosed as per  
WHO guidelines 
2. Age less than 40 years 
3. No diabetes related complications at time of enrollment into 
the study 
4. No other co-existing autoimmune disease 
5. Diabetes patients on oral hypoglycemic agents with or 
without Insulin 
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Exclusion criteria 
1. Not willing to participate in the study after clear explanation 
2. History of diabetic ketoacidosis in the past 
3. Micro or macro vascular diabetic complications 
4. Pregnant diabetes patients 
5. Patients known to have pancreatitis disease 
6. Patients with autoimmune disease 
7. Patients on drugs that may be the cause of diabetes 
 After meticulous assessment of inclusion and exclusion criteria, 82 patients 
were enrolled in this study. Verbal explanation about the study was clearly 
enlightened to the participants and their doubts in the study was addressed 
and clarified. From those are willing to enroll in the study an informed 
consent in the prescribed format submitted to ethical committee was 
obtained. Participants who can’t understand English language, the consent 
form was obtained in their mother tongue (Tamil) so that the participants can 
have better understanding about the study details. 
53 
 
From the eligible subjects, history such as the duration of diabetes, onset of 
the disease, cause of detection and family history of diabetes with types were 
asked and noted in the prescribed format. Regarding treatment, details about 
diabetes management as well as other diseases were then recorded.  
 These subjects were subjected to general examination and anthropometric 
measurements were recorded. In anthropometry height, weight, calculation 
of BMI by the formula using height and weight, waist hip ratio were 
recorded. External markers for insulin resistance like acanthosis nigricans, 
hirsutism were made out by inspection. 
 Tape marked in centimeters was used to measure the height and it was 
measured to nearest centimeter. To measure the height participants were 
requested to stand upright without any foot wear with heels together. They 
are requested to look forward while measuring the height. Universally 
accepted and calibrated weighing machine was utilized to assess the weight 
of the participants. Weight was calibrated to the nearest rounded kg without 
decimals. Weigh machine was kept on a level flat surface while measuring. 
Wearing of thin cloths which will not interfere with weight was allowed. To 
assess the obesity or overweight body mass index (BMI) was calculated. 
BMI was calculated by dividing weight in kilogram by height in meter 
square. Reference for body mass index in our study was adopted from the 
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guidelines released by Health Ministry- Government of India, Indian 
Council of Medical Research (ICMR) and the National Institute of Nutrition 
(NIN). 
Body mass index for Indian population: 
 
Less than 18.4 Underweight 
18.5 - 22.9 Normal 
23 - 24.9 Overweight 
More than 25 Obese 
 
Measurement of blood pressure was done in a quiet room, patient in seated 
position for 5 minutes. Well calibrated and accepted blood pressure machine 
with appropriate cuff size working on mercury scale was used to measure 
the resting blood pressure. Blood pressure was recorded in the two arms and 
the highest of these two recording were mentioned. Patients who are on 
medication for blood pressure control were allowed the take the morning 
dose as scheduled and BP was recorded under the productive cover of 
antihypertensive only.  
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Waist circumference: 
  Waist circumference is used to assess the central obesity. Measurement of 
waist circumference was done at the mid-point between the iliac crest and 
sub costal margin with the help of non-stretching tape. Waist circumference 
of the participants where measured in standing position with feet together 
and measurement was rounded to the nearest whole number.  Thin layer of 
cloth is allowed on measuring the circumference. For Indian men cut-off 
limit for waist circumstances is below 90 cm as opposed to 102 cm 
worldwide and in case for Indian women it is 80 cm as opposed to 88 cm at 
the worldwide. 
Assays and calculations: 
Under sterile precaution, sufficient blood samples were drawn both in fasted 
and post prandial state. Biochemical investigations were done at quality 
control laboratory at Institute of Diabetology, RajivGandhiGovernment 
GeneralHospital, Chennai. Fasting samples were utilized for assessing 
fasting plasma glucose, lipid profile, renal parameter, c-peptide, insulin auto 
antibodies like GAD 65 and IA-1. Postprandial blood sample was drawn 2 
hours from the ingestion of breakfast with scheduled anti diabetic 
medication the patient is taking already.  
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Fasting plasma glucose and post prandial plasma glucose were tested by 
Glucose Oxidase – Peroxidase method using the validated semi-autoanalyser 
named Erba Mannheim cehm plus-7. 
Urea was estimated by Urease-Glutamte dehydrogenase (GLDH) method 
and creatinine was assessed by modified Jaffe’s method by means of the 
same semi-autoanalyser named Erba Mannheim cehm plus-7.  
With the use of semi-autoanalyser named Erba Mannheim cehm plus-7. lipid 
profile was estimated. Total cholesterol was assessed by cholesterol oxidase-
peroxidase (CHOD-PAP) method, triglycerdies by Glycerophosphate 
oxidase-peroxidase (GPO-PAP) method and high density lipoprotein was 
estimated by third generation direct homogeneous assay. Low density 
lipoprotein was calculated by using the Friedewald equation for the sample 
with triglycerides less than 400mgs/dl. Urine was test for the estimation of 
spot protein by 3% sulphosalicylic acid test and normal urine spot protein 
patients were included in the study. 
Immunological assays such as estimation of C-peptide level and 
autoantibodies such as GAD-65 as well as IA-2 were done at central lab, 
department of Immunology, the TamilNaduDr.M.G.R.MedicalUniversity, 
Chennai using the ELISA technique in quality control Elisa reader made be 
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Biorad. GAD-65 estimation was done by using the Euroimmun Anti-GAD 
IgG Elisa kit and IA-2 was done by using Euroimmun Anit- IA2 IgG Elisa. 
To determine the presence of metabolic syndrome in these individuals, 
NCEP ATP III (National Cholesterol Education Program Adult Treatment 
Panel III) 
Criteria were used. Following are the criteria  
1. Blood pressure ≥ 130/85 mmHg or ≤ 130/85 mmHg with 
antihypertensive medications. 
2. Fasting plasma glucose ≥ 6.1 mmol/l (110 mgs/dl) 
3. HDL cholesterol < 40 mg/dl for men or < 50mg/dl for women,  
4. Triglycerides > 150 mgs/dl or patients on medication with fibrate 
drugs  
5. Waist circumference (WC) cut-offs were taken as >90 cm for males 
and >80 cm for females to define overweight  
As Indians have higher body fat content than their western counterparts for 
the same BMI, lower cut-offs of waist circumference were used as suggested 
by Asia-Pacific guidelines in contrast the globally accepted waist 
circumference ≥ 102 cm for men or ≥ 88 cm for women.  
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The diagnosis of the metabolic syndrome required individuals to have at 
least three of these five criteria. Because all of the subjects in this report had 
diabetes, they only had to have two of the remaining four criteria to meet the 
definition. 
Statistical method 
  Data reported in this study include descriptive statistics of the 
participants at the time of enrollment. Qualitative variables in this study such 
as sex, family history etc are analyzed by chi-square test. The quantitative 
data in this study were analyzed using independent sample t tes 
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RESULTS 
Results: Total number of participants in this study was 82 in number. In 
this study group 43(52.44%) were females and 39 (47.56%) were males. On 
analysis of 82 people for the presence of autoantibodies to GAD-65 and IA-
2, 7 were positive which represents 8.53% in percentage. Of the two 
autoantibodies, antibodies to GAD was prevalent in adults and was seen in 6 
peoples whereas IA-2 was seen in one patient and none of the patients in this 
study showed positivity for both autoantibodies. 
Age and autoantibodies positivity: 
 Out of 7 positive for autoantibodies patients, 5 were in the age group 
between 21 to 30 years of age and 2 were in between the age group of 31-40 
years of age. Although there was no statistical significance in the age 
distribution between autoantibodies positive group from the autoantibodies 
negative group, clustering of autoantibodies positive cases occurs earlier. 
Sex and autoantibodies positivity: 
 In sex ratio within the autoantibody positive group, out of 7 
autoantibodies positive 5 (71.4%) of them were male and 2(28.6%) of them 
were female. 
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 On analyzing the sex ratio between antibody positive group vs 
antibody negative group, out of 39 males participated 5(12.8%) were 
positive for autoantibodies  and in case of female out of 43 participants 
2(4.7%) were positive for autoantibodies. There was no statistical 
significance between these two groups. 
Family history of Diabetes and autoantibodies positivity 
 Both the autoantibodies positive group and negative group did not 
show any variations regarding the prevalence of family history in their 
group. In positive group 2 patients had a positive family history of diabetes 
out of total 7 patients. In negative group 42 cases out of 75 cases showed 
positive family history.  
Duration of Diabetes: 
 Antibodies positive group did not vary from that of negative group in 
the aspect of duration of the study. Out of 7 autoantibodies positive patients, 
6 patients presented with duration of diabetes less than 2 years where as out 
of 75 autoantibodies negative group 51 cases presented with less than 2 
years duration. 
 The demographic parameters such as age, sex, duration of diabetes 
and family history did not differ between the two groups. So using the age or 
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family history as cut off to diagnose type 1 or type 2 diabetes clinically 
becomes blurred.  
Clinical and Laboratory profile: 
Body Mass Index: (BMI)  
Reference for body mass index in our study was adopted from the guidelines 
released by Health Ministry- Government of India, Indian Council of 
Medical Research (ICMR) and the National Institute of Nutrition (NIN). 
Body mass index between these two groups showed no statistical variations 
which is also required as screening eligibility for the study. On comparing 
the median BMI between these two groups autoantibodies positive group 
median BMI (22.47 ± 2.03) was lower than that of antibodies negative group 
(24.45±3.88). 
Waist circumference and autoantibodies positivity 
 As per the ICMR recommendation; cut off limit for waist 
circumference is below 90cms for Indian men and 80 cms for Indian women. 
In case of male population in our study, out of 5 autoantibodies positive 
patient one patient had central obesity whereas 27 patients of total 75 
autoantibodies negative patients had central obesity of waist circumference 
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more than 90 cms. On statistical analysis these findings became not 
significant. 
In case of female participants in our study none of the antibody positive 
patient had central obesity whereas 30 out of 43female participants had waist 
circumference more than 80 cms fitting in the criteria for central obesity. 
However autoantibodies positive female number is less this cannot be 
extrapolated to a huge population. On statistical analysis of these parameters 
comparing both the groups, waist circumference was not varying between 
the two groups. 
Fasting C-peptide concentration and autoantibodies positivity: 
Estimation of fasting C-peptide which is surrogate marker of endogenous 
insulin secretion was done in all the 82 participants and compared with the 
two groups.  
Comparison revealed statistical significance between the two groups. All the 
7 autoantibodies patients showed marked reduction in the plasma fasting C-
peptide concentration. In the autoantibodies negative group out of 75 
patients, only 5 patients showed significant low levels of plasma C-peptide 
concentration. 
Metabolic syndrome and autoantibodies positivity 
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Estimation of systolic and diastolic blood pressure between the two groups 
was done to analyze the prevalence of metabolic syndrome. Mean systolic 
BP in antibody positive group is 117.14± 4.88 whereas in the antibody 
negative group is 117 ± 7.01 which was statistically insignificant. Mean 
diastolic BP in the antibody positive group is 82.29 ± 7.06 where mean 
diastolic BP in the antibody negative group is 78.83 ± 5.47 which is also 
statistically insignificant. 
Triglycerides and autoantibody positivity 
 Mean triglycerides level in autoantibody positive group is 186.86 ± 
34.84 whereas mean triglycerides level in autoantibody negative group is 
164.47 ± 63.50. Statistical analysis revealed there is no significant difference 
between these two groups. 
HDL and autoantibody positivity 
 HDL analysis revealed statistical significance between the two group. 
Mean HDL in autoantibody group is 41 ± 1.41 whereas in autoantibody 
negative group is 38.61 ± 4.62. 
Insulin usage in the management of diabetes and autoantibodies positivity 
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  Out of 7 autoantibodies positive patients 2 patients were on insulin 
before the enrollment into study and 16 patients out of 75 patients in 
autoantibodies negative group were on insulin before the start of the study. 
Statistically insulin usage between the two groups was not significant. 
Fasting plasma glucose and autoantibodies positivity 
 Fasting plasma glucose between the autoantibodies positive and 
autoantibodies negative group did not reveal any statistical significance. 
Mean fasting glucose in autoantibodies positive group is 179 ± 14.99 
whereas in the autoantibodies negative group is 173.99 ± 25.86. 
Thus the BMI and Waist circumference which are the markers for assessing 
obesity is not fruitful to differentiate between autoimmune type 1 and type 2 
diabetes mellitus. 
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Discussion 
                         In our study , the prevalence of autoantibodies –GAD and 
IA-2  in phenotypically diagnosed type 2 diabetes mellitus is 8.53%  
whereas the prevalence in various studies are 
1.Georgeanna J .Klingensmith et al– in Treatment Option for Type 2 
Diabetes in Adolescent and Youth study (TODAY) the prevalence of 
autoantibodies in patients with clinically to have type 2 diabetes mellitus is 
9.8%.The number of participants in the study was 1,206. 
Bernard Zinman et al – A Diabetes Outcome Progression Trial (ADOPT)  
which was conducted to assess the autoantibody GAD in patients diagnosed 
as type 2 diabetes mellitus. The prevalence is this study is 4.2% for 
autoantibody to GAD. In this study 4134 type 2 diabetes mellitus 
participated. 
United Kingdom Prospective Diabetes Study (UKPDS) – The major 
landmark study in diabetes showed the overall prevalence of GAD 
antibodies was 10%. 
Tiinamaija Tuomi et al - Large scale study conducted involving 1122 type 2 
diabetic subjects for the prevalence of GAD antibodies in western Finland. 
The prevalence of GAD antibodies was 9.3%Parameters 
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Parameters TODAY 
Study 
ADOPT 
Study 
Present 
Study 
Mean Age 
(in years) 
Ab positive 13 56.5 29.71 
Ab negative 14 57 30.67 
Duration of 
DM 
Ab positive 2.5  1.37 
Ab negative 1.9  1.9 
BMI Ab positive 29.1 31.4 22.47 
Ab negative 34.9 32 24.45 
SBP Ab positive 110.5 131.2 117.14 
Ab negative 115 132.9 117.17 
DBP Ab positive 64.7 78.6 82.29 
Ab negative 68.3 79.7 78.83 
Insulin use Ab positive 54.2%  28.5% 
Ab negative 38.8%  21.33% 
Low  Ab positive   100% 
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C-Peptide Ab negative   6.6% 
Triglycerides Ab positive 77 147.9 186.86 
 Ab negative 106.5 164.7 164.47 
HDL Ab positive 43 48.7 41 
 Ab negative 39 46.79 38.6 
       The demographic profile and biochemical profile of our study is 
consistent with the findings of large study conducted at various parts of the 
world.  
Thus antibody positive and negative groups did not differ with respect to 
age, sex, family history of diabetes, duration of diabetes, body mass index, 
waist circumference, fasting plasma glucose. These two groups also show 
similarity in relation to metabolic syndrome parameters such as blood 
pressure, triglycerides estimation. However there is statistical significance (p 
< .005) noted in HDL parameter where HDL is low in antibody negative 
groups  
The fasting C-Peptide was low in all the patients belonging to antibody 
positive group with P value < 0.001. These results indicate that type 2 
diabetes in young and type 1 diabetes have similar clinical and metabolic 
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parameters. Thus diagnosing diabetes on the basis of clinical criteria such as 
age, family history, obesity becomes blurred in young individuals. 
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Group Statistics 
 
Auto 
Antibody n Mean 
Std. 
Deviation 
Std. 
Error 
Mean P value 
Age Yes 7 29.71 3.592 1.358 
0.668  No 75 30.63 5.474 .632 
Duration (in 
years) 
Yes 
7 1.371 .8845 .3343 
0.207 
 No 74 1.950 1.1684 .1358 
BMIKg/m2 Yes 
7 
22.474
3 
2.03219 .76810 
0.188 
 No 
75 
24.452
8 
3.87623 .44759 
Waist(Cms) Yes 7 80.71 6.075 2.296 
0.214 
 No 75 85.40 9.681 1.118 
SBP Yes 7 117.14 4.880 1.844 0.991 
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(mmhg) 
 No 75 117.17 7.007 .809 
DBP 
(mmhg) 
Yes 
7 82.29 7.064 2.670 
0.123 
 No 75 78.83 5.473 .632 
TGL 
(mgs/dl) 
Yes 
7 186.86 34.840 13.168 
0.168 
 No 75 164.47 63.504 7.333 
HDL(mgs/d
l) 
Yes 
7 41.00 1.414 .535 0.005 
 No 75 38.61 4.623 .534  
FPG(mg/dl) Yes 7 179.00 14.989 5.665 
0.616 
 No 75 173.99 25.865 2.987 
PPG(mg/dl) Yes 7 245.00 39.323 14.863 
0.288 
 No 75 262.97 42.190 4.872 
P value <0.005-significant    >0.005 Not significant 
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The findings of autoantibodies positive patients who took part in our study 
were consistent with other studies. Diabetes diagnosed as type 2 in young 
individuals may have clinically in apparent islet cell autoantibodies which 
may culminate in metabolic derangement. 
We conclude that young patients diagnosed as type 2 diabetes mellitus be 
screened for the presence of autoantibodies. 
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LIMITATIONS OF THE STUDY 
One limitation of the study is that our study involved low number of 
participants in comparison to other studies. Hence these results need to be 
confirmed in large group of patients and longitudinal studies. 
HbA1c was not done in our study to assess exact glycemic control. 
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CONCLUSION 
Diagnosing type 2 diabetes in young individuals by using the classical 
clinical criteria such as age and weight has to be revised as these patients 
may have evidence for autoimmune destruction of islet of pancreas. These 
antibody positive individuals have similar demographic, clinical as well as 
biochemical profile as that of type 2 diabetes. Thus screening autoantibodies 
is useful to distinguish between type 1 diabetes and type 2 diabetes in young.  
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PROFORMA 
THE PRESENCE OF GAD & IA-2 ANTIBODIES IN YOUNG ADULTS DIAGNOSED AS TYPE 2 
DIABETES MELLITUS 
 Name :       Patient ID No: 
Age/Sex :      IP No : 
 
Patient characteristics Drugs 
Diabetes    Yes or No ❏Sulphonylurea 
❏ Duration ❏ Metformin / Pioglitazone 
❏ Mode of Onset: Insidious or sudden ❏ α – glucosidase inhibitors 
❏ Symptoms : Polyuria / Polydipsia / Wt. loss ❏ Others :   
❏ Family history: 
❏  Treatment for  
      other illness 
❏ Any other illness:  ❏ Ketosis prone 
❏ H/O GDM/ BOH: ❏ Microvascular complication 
❏ Childhood rashes  
     with lymphadenopathy 
❏Macrovascular complication 
 
CLINICAL PARAMETERS 
Pulse bpm Blood Pressure mmhg 
❏ Height: ❏ Weight:  
❏ BMI: ❏ W/H : 
❏ Acanthosis nigricans: ❏ Xanthelesma/Xanthoma: 
 
Investigations: 
Glycemic profile  RFT 
FPG  mg/dl Bl.urea  mg/dl 
PPG  mg/dl Sr.Creatinine  mg/dl 
C-peptide   Urine spot protein  Mg/day 
 LIPID PROFILE 
Total 
cholesterol 
 Mgs/dl INSULIN ANTIBODIES 
 TGL  Mgs/dl GAD Positive Negative 
HDL  Mgs/dl IA-2 Positive Negative 
VLDL  Mgs/dl 
LDL  Mgs/dl 
 
KEY WORDS 
Y   yes 
N   no 
M   male 
F   female 
BMI   Body mass index 
GDM   Gestational diabetes mellitus 
BOH   Bad obstetric history 
SBP   Systolic blood pressure 
DBP   Diastolic blood pressure 
FPG   Fasting plasma Glucose 
PPG   Post prandial plasma Glucose 
TGL   Triglycerides 
HDL   High Density Lipoprotein 
LDL   Low Density Lipoprotein 
VLDL  Very Low Density Lipoprotein 
GAD   Glutamic Acid Decarboxylase 
IA-2   Insulinoma Associated protein 2 
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1 Karthikeyan M 34 4 I YES Nil Y Y Nil 88 130 84
2 Juliet Shakina F 31 2 I YES GDM +ve Y Y Nil 84 120 78
3 Sharmila Begum F 28 2 I YES Nil Y Y Nil 78 110 80
4 Ananthi F 27 2 I NO Nil Y Y Nil 88 120 86
5 Gomathi F 36 4 S YES GDM +ve Y Y N 74 110 80
6 Diana F 26 1.5 I YES Nil Y Y N 78 120 80
7 Sulthana F 39 4 I NO Nil Y Y N 82 130 80
8 Samuthrakani F 35 2 I YES Nil Y Y Y 84 110 80
9 Sathya F 30 3 I NO GDM +ve Y Y N 76 130 80
10 Venugopal M 33 1 I YES Nil Y Y N 82 120 80
11 Selvakumar M 37 3 I NO Nil Y Y N 88 120 90
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12 Ramesh M 38 2 I YES Nil Y Y N 82 110 80
13 Mythili F 32 4 I NO Nil Y Y N 78 120 80
14 Suresh Kumar M 31 1 I NO Nil Y Y Y 86 120 90
15 Nirupam F 31 1 I NO Nil Y Y Y 84 120 70
16 Dhanasekar M 37 3 I YES Nil Y Y N 82 130 80
17 Selvi F 15 0.8 I YES Nil Y Y 78 120 80
18 Mahalingam M 31 2 I NO Nil Y Y N 82 110 80
19 Thasleema F 16 0.6 I YES Nil Y Y N 88 120 80
20 Thulasi F 37 3 NO Nil Y Y N 76 120 70
21 Raja Manickkam M 32 1 I NO Nil Y Y N 78 120 80
22 Amalraj M 29 1 I YES Nil Y Y N 76 120 80
23 Das M 33 1 NO Nil Y Y N 84 110 90
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24 Pandidurai M 32 1 I YES Nil Y Y N 78 120 80
25 Geetha F 30 3.5 I YES GDM +ve Y Y Y 82 120 70
26 Dhanalakshmi F 32 3.2 I YES GDM +ve Y Y Y 72 110 80
27 Sarath Babu M 30 1.5 I NO Nil Y Y Y 84 120 80
28 Balamurugan M 35 2 I NO Nil Y Y N 86 110 80
29 Dhilip M 24 1 I YES Nil Y Y Y 78 120 80
30 Raju M 28 0.6 I NO Nil Y Y N 82 120 70
31 Selvam M 35 2 NO Nil Y Y Y 78 110 90
32 Selvi F 38 1.5 I NO Nil Y Y N 80 120 90
33 Jeevan M 34 1 I NO Nil Y Y N 82 120 80
34 Udhayakumari F 25 1 I NO Nil Y Y N 82 120 80
35 Sumathi F 30 0.6 I NO Nil Y Y N 82 120 80
36 Pooshanam F 21 2 I NO Nil Y Y N 82 120 80
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37 Chales M 34 3.8 I YES Nil Y Y Y 72 110 80
38 Venkatesan M 30 1 I NO Nil Y Y N 76 120 70
39 Mani M 35 4 I NO Nil Y Y Y 88 110 70
40 Subash M 38 2.6 I YES Nil Y Y Y 84 110 80
41 Annapoorani F 24 2 I YES GDM +ve Y Y Y 76 120 80
42 Thurab Ali M 36 0.8 S YES Nil Y Y Y 80 120 70
43 Rajaram M 27 2.8 I YES Nil Y Y N 78 120 80
44 Annalakshmi F 31 1.5 I YES Nil Y Y N 82 120 80
45 Jeya F 29 1 I YES Nil Y y N 72 110 80
46 Raman M 35 1 I NO Nil Y Y N 78 120 70
47 Thiyagarja M 35 4 I YES Nil Y Y N 84 110 80
48 Chitra F 32 3.2 I YES GDM +ve Y Y N 84 120 80
49 Martin M 23 0.6 I NO Nil Y Y N 84 110 80
50 Kavitha F 30 4 I NO GDM +ve Y Y N 82 120 80
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51 Karpagam F 35 0.6 I YES Nil Y Y N 78 120 70
52 Kumar M 30 2 I YES Nil Y Y N 84 110 90
53 Jansi F 28 0.6 I YES Nil Y Y N 82 120 80
54 Yegavalli F 36 4 I YES Nil Y Y N 82 110 80
55 Lakshmanan M 30 3 I YES Nil Y Y N 82 120 80
56 Pavani F 29 2 I YES Nil Y Y N 84 120 70
57 Saraswathy F 33 2 I YES Nil Y Y N 80 120 80
58 Sasikala F 34 2 I NO Nil Y Y N 78 110 80
59 Thirumal M 34 0.6 I NO Nil Y Y N 76 130 80
60 Kalpana F 23 1 Yr I YES GDM +ve Y Y N 74 120 80
61 Amudha F 30 0.6 I NO GDM +ve Y Y N 82 130 70
62 Dhanalakshmi F 32 2 I YES GDM +ve Y Y N 82 134 80
63 Sarala F 27 2 I NO GDM +ve Y Y N 82 110 80
64 Radha F 27 2 I YES GDM +ve Y Y N 80 120 80
65 Pushpa F 27 0.5 I YES Nil Y Y N 84 120 70
66 Sivakumar M 35 4 I NO Nil Y Y N 78 120 80
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67 Yaseer M 35 3 I NO Nil Y Y N 79 120 70
68 Sivaraman M 27 1 I NO Nil Y Y N 80 110 80
69 Pushpa Malliga F 34 2 I YES Nil Y Y N 88 110 80
70 Wasim Akram M 27 2.5 S NO Nil Y Y Y 74 100 70
71 Jeevitha F 20 0.9 S NO Nil Y Y Y 71 110 80
72 Ramzan Beevi F 27 3 I YES GDM +ve Y Y N 78 120 80
73 Mohamed Rafiq M 34 1 I NO Nil Y Y N 78 120 80
74 Sentilkumar M 32 1.5 I YES Nil Y Y N 78 120 90
75 Sarhu Nisha F 30 1 I YES Nil Y Y N 82 110 70
76 Murugeswari F 38 3 I YES Nil Y Y N 80 120 90
77 Muneeswaran M 29 0.6 I YES Nil Y N 88 110 80
78 Ramesh M 36 1 I NO Nil Y Y N 76 120 90
79 Jeya Bharathi F 32 3 I NO Nil Y Y N 78 120 80
80 Rajendra Prasath M 31 0.2 S NO Nil Y Y N 79 100 80
81 Meena F 15 0.1 S YES Nil Y Y Y 84 100 70
82 Raja M 17 0.1 S YES Nil Y Y Y 76 114 70
Total 83 1.9
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180 106 32.71 104 YES 180 255 Normal 28 0.9 232 225 32 45 155
145 49 23.3 74 NO 163 221 Normal 29 0.8 185 171 39 34 112
142 52 25.8 81 YES 173 229 Normal 23 1.0 165 150 41 30 94
152 48 20.78 73 NO 202 331 LOW 28 1.0 183 195 41 39 103
154 77 32.4 102 YES 192 287 Normal 18 0.9 194 167 35 33 126
157 53 21.5 79 NO 158 248 Normal 22 0.7 209 163 36 33 130
158 87 34.85 105 YES 183 278 Normal 27 0.8 210 122 41 22 147
144 47 22.7 74 NO 165 217 Normal 21 0.7 174 112 37 22 114
154 84 35.41 110 YES 189 247 Normal 18 0.8 224 199 29 40 155
169 80 28.01 95 NO 180 317 Normal 28 1.0 199 180 36 36 127
165 60 22.03 81 NO 183 217 LOW 23 0.8 175 130 42 26 107
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150 46 20.4 73 NO 163 215 Normal 18 0.9 201 253 27 51 123
155 46 19.1 71 NO 159 209 Normal 21 0.7 178 108 36 22 120
165 70 23.8 81 NO 161 228 LOW 40 1.2 239 172 41 34 164
150 55 24.4 86 YES 180 233 Normal 20 0.9 179 163 40 33 106
170 72 24.91 85 NO 167 263 Normal 21 1.0 110 70 45 14 51
158 60 24.03 91 YES 210 325 LOW 33 0.7 150 187 46 37 67
163 62 23.33 103 YES 199 317 Normal 20 1.0 191 165 37 33 121
157 58 23.53 85 NO 151 265 Normal 19 0.7 180 132 42 26 112
164 74 27.5 92 NO 183 274 Normal 18 0.8 174 98 46 20 108
160 74 28.9 105 YES 180 245 Normal 28 1.1 163 122 42 25 96
167 81 29.1 87 YES 155 215 Normal 23 0.9 202 143 38 29 135
175 70 22.1 84 NO 168 261 Normal 18 0.8 145 111 47 22 76
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162 53 20.2 79 NO 210 334 LOW 23 0.9 183 134 39 27 117
153 64 27.3 93 NO 171 253 LOW 30 0.9 189 172 38 34 117
153 63 26.9 98 YES 155 222 Normal 31 1.0 211 108 41 22 148
166 71 25.7 91 NO 161 220 LOW 38 1.2 189 174 42 35 112
161 54 20.83 76 NO 151 209 Normal 26 0.8 130 112 42 22 66
171 63 21.24 87 NO 163 237 Normal 33 1.0 187 130 41 26 120
164 67 24.9 89 NO 189 255 Normal 22 0.7 188 145 39 29 120
170 72 24.91 81 NO 192 277 Normal 28 0.8 182 190 28 38 116
155 63 26.22 81 YES 170 231 Normal 30 1.0 174 123 36 25 113
161 60 23.1 83 NO 220 340 Normal 27 1.1 197 117 37 23 137
149 48 21.62 80 NO 201 322 Normal 16 0.7 215 356 40 71 104
160 67 26.17 85 NO 210 318 Normal 28 0.9 177 154 45 31 101
149 47 21 81 NO 151 227 Normal 23 0.8 160 137 41 27 92
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164 64 23.7 81 NO 132 224 Normal 21 0.9 171 102 43 20 108
173 59 19.71 75 NO 154 284 Normal 19 0.7 152 90 42 18 92
173 58 19.39 79 NO 211 373 Normal 22 0.9 252 153 42 50 160
170 55 19 73 NO 205 351 Normal 35 1.2 252 301 39 60 153
143 50 24.45 83 NO 183 294 Normal 27 0.9 191 173 41 35 115
166 61 22.1 81 NO 124 302 LOW 21 0.7 174 136 45 27 102
163 78 29.32 98 YES 145 253 Normal 18 0.9 213 194 38 43 132
147 55 25.4 86 YES 180 247 Normal 19 0.9 202 218 41 44 117
147 55 25.4 91 YES 173 234 Normal 18 0.7 185 152 40 30 115
165 67 24.6 84 NO 140 254 Normal 23 0.6 184 142 38 28 118
174 64 21.1 79 NO 165 324 Normal 20 0.7 152 89 43 18 91
144 65 31.3 106 YES 198 270 Normal 18 0.8 146 225 27 45 74
167 60 21.58 79 NO 201 256 Normal 24 1 131 109 38 22 71
144 41 19.5 81 NO 148 251 Normal 20 0.9 206 215 41 43 122
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153 74 31 105 YES 135 245 Normal 21 1 205 245 37 49 119
171 68 23.3 79 NO 162 264 Normal 36 1 186 214 35 43 108
160 62 24.2 84 NO 136 241 Normal 17 0.8 170 106 45 21 104
151 52 22.8 81 NO 230 340 Normal 23 0.8 234 256 41 51 142
180 78 24 84 NO 191 387 Normal 19 1.2 185 210 34 42 109
147 43 19.8 75 NO 165 239 Normal 17 0.5 153 74 42 15 96
153 57 24.34 81 NO 147 253 Normal 20 1.1 207 242 35 48 124
155 51 21.25 75 NO 141 245 Normal 17 0.8 185 284 41 57 87
161 67 25.8 86 NO 136 185 Normal 19 1 115 73 39 15 61
148 78 35.6 102 NO 145 256 Normal 21 0.9 194 200 34 40 120
145 53 25.2 84 YES 156 284 Normal 18 0.7 194 206 29 41 124
147 50 23.15 89 NO 141 263 Normal 19 0.8 162 120 41 24 97
153 54 23.0 79 NO 180 233 Normal 21 0.8 201 152 36 30 135
163 60 25.3 85 NO 201 311 Normal 18 0.8 141 163 37 33 71
150 40 19.7 74 NO 190 233 LOW 24 0.8 209 191 42 38 129
167 61 21.86 74 NO 196 273 Normal 19 1.0 163 125 40 25 98
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170 66 22.84 79 NO 135 201 Normal 24 0.8 172 98 42 20 110
168 50 21.71 81 NO 182 247 LOW 27 0.7 214 245 41 49 124
154 55 22.3 85 NO 173 220 Normal 19 0.9 163 134 42 27 94
187 79 22.57 83 NO 144 201 Normal 18 1.0 185 91 39 18 128
154 52 21.9 75 NO 190 281 Normal 21 0.9 162 98 44 20 98
160 65 25.39 86 NO 191 238 Normal 21 1.0 177 199 40 40 97
166 67 24.3 84 NO 200 260 Normal 22 0.8 182 104 39 21 122
168 59 21 76 NO 153 217 Normal 22 1.1 203 241 41 48 114
145 60 28.53 98 YES 160 220 Normal 18 0.8 163 187 37 37 89
160 61 23.82 79 NO 180 250 Normal 23 0.9 199 252 34 50 115
168 51 23.6 84 NO 174 239 LOW 28 1.1 184 201 38 40 106
164 74 27.6 96 NO 166 219 Normal 24 0.9 214 301 41 60 113
140 50 26.3 94 NO 193 270 Normal 19 1.1 186 324 25 65 96
169 68 23.8 91 NO 190 276 Normal 23 0.9 187 225 32 45 110
137 35 18.62 69 NO 245 302 LOW 22 0.7 148 118 39 24 85
138 37 19.47 72 NO 227 286 Normal 20 0.8 126 75 38 15 73
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